{
    "organizations": [],
    "uuid": "0d63d90217f9964c026a49fd064ed2477eb71187",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-vaxart-says-data-shows-orally-admi/brief-vaxart-says-data-shows-orally-administered-norovirus-tablet-vaccine-was-well-tolerated-idUSFWN1QK0QK",
    "ord_in_thread": 0,
    "title": "BRIEF-Vaxart Says Data Shows Orally Administered Norovirus Tablet Vaccine Was Well-Tolerated",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "March 2 (Reuters) - Vaxart Inc:\n* VAXART - DATA SHOWS ORALLY ADMINISTERED NOROVIRUS TABLET VACCINE WAS WELL-TOLERATED, GENERATED ROBUST SYSTEMIC AND LOCAL INTESTINAL IMMUNE RESPONSES\n* VAXART INC - DID NOT SEE ANY EVIDENCE OF ANTI-VECTOR IMMUNITY WITH NOROVIRUS ORAL TABLET VACCINE Source text for Eikon: Further company coverage:\n ",
    "published": "2018-03-02T21:24:00.000+02:00",
    "crawled": "2018-03-03T17:41:03.029+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "march",
        "reuters",
        "vaxart",
        "inc",
        "vaxart",
        "data",
        "show",
        "orally",
        "administered",
        "norovirus",
        "tablet",
        "vaccine",
        "generated",
        "robust",
        "systemic",
        "local",
        "intestinal",
        "immune",
        "response",
        "vaxart",
        "inc",
        "see",
        "evidence",
        "immunity",
        "norovirus",
        "oral",
        "tablet",
        "vaccine",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}